TY - JOUR
T1 - Endocrine profile in a patient with familial breast cancer. A case‐control study
AU - Lynch, Henry T.
AU - Harris, Randall E.
AU - Lynch, Jane F.
AU - Marrero, Kathleen
AU - Maloney, Kathleen
AU - Fishman, Jack
PY - 1979/11
Y1 - 1979/11
N2 - Urinary and blood hormonal profiles were studied throughout a monthly cycle in a patient with familial breast cancer. Two comparison cohorts (one high-risk and one low-risk) were studied concurrently. Findings disclosed that our breast cancer-affected patient showed a distinctive hormonal pattern characterized by significant elevation throughout the cycle of plasma estrone, estradiol, and prolactin. Save for a depression in plasma FSH in the early follicular phase, this hormone, as well as LH and progesterone patterns in our patient, were similar to the comparison cohorts. Urinary estrone and estradiol patterns in our patient were elevated early in the follicular phase. Our patient also showed a depression in urinary estrone, estradiol, and estriol following ovulation, which persisted throughout the luteal phase. Blood and urinary hormone patterns in the high-risk cohort were not demonstrably different from the low-risk cohort, with the exception of plasma prolactin. The results on the latter hormone showed an unexpected significant depression throughout most of the menstrual cycle in this low-risk cohort. We conclude that estrone and estradiol elevations, as clearly evidenced in out breast cancer-affected patient, may provide clues that ultimately might be used as an etiologic discriminant for breast cancer risk and which may also play a pathogenic role in this disease. Since this involved a single patient, our conclusions must be interpreted cautiously.
AB - Urinary and blood hormonal profiles were studied throughout a monthly cycle in a patient with familial breast cancer. Two comparison cohorts (one high-risk and one low-risk) were studied concurrently. Findings disclosed that our breast cancer-affected patient showed a distinctive hormonal pattern characterized by significant elevation throughout the cycle of plasma estrone, estradiol, and prolactin. Save for a depression in plasma FSH in the early follicular phase, this hormone, as well as LH and progesterone patterns in our patient, were similar to the comparison cohorts. Urinary estrone and estradiol patterns in our patient were elevated early in the follicular phase. Our patient also showed a depression in urinary estrone, estradiol, and estriol following ovulation, which persisted throughout the luteal phase. Blood and urinary hormone patterns in the high-risk cohort were not demonstrably different from the low-risk cohort, with the exception of plasma prolactin. The results on the latter hormone showed an unexpected significant depression throughout most of the menstrual cycle in this low-risk cohort. We conclude that estrone and estradiol elevations, as clearly evidenced in out breast cancer-affected patient, may provide clues that ultimately might be used as an etiologic discriminant for breast cancer risk and which may also play a pathogenic role in this disease. Since this involved a single patient, our conclusions must be interpreted cautiously.
UR - http://www.scopus.com/inward/record.url?scp=0018629322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018629322&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(197911)44:5<1860::AID-CNCR2820440545>3.0.CO;2-I
DO - 10.1002/1097-0142(197911)44:5<1860::AID-CNCR2820440545>3.0.CO;2-I
M3 - Article
C2 - 498052
AN - SCOPUS:0018629322
VL - 44
SP - 1860
EP - 1869
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 5
ER -